The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes

Journal of the American College of Cardiology

Volumn 46, Issue 8, 2005, Pages 1425-1433

  Ray, Kausik K ^a   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ACUTE DISEASE; ARTERY ENDOTHELIUM; ARTERY THROMBOSIS; ARTERY WALL; BLOOD CLOTTING; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SOLUBILITY; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LIPOPROTEIN BLOOD LEVEL; MULTIPLE SCLEROSIS; NONHUMAN; PHARMACODYNAMICS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW;

ACUTE DISEASE; ANGINA, UNSTABLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MYOCARDIAL INFARCTION; SYNDROME;

EID: 26844564725     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.05.086     Document Type: Review

References (71)

1. G. Rioufol, G. Finet, I. Ginon Multiple atherosclerotic plaque rupture in acute coronary syndrome a three-vessel intravascular ultrasound study Circulation 106 2002 804 808
2. D. Steinberg, A. Lewis Conner memorial lecture. Oxidative modification of LDL and atherogenesis Circulation 95 1997 1062 1071
3. K.K. Ray, C.P. Cannon Time to benefit an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease Crit Pathways Cardiol 4 2005 43 45
4. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
5. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
6. J.D. Pearson Endothelial cell function and thrombosis Baillieres Best Pract Res Clin Haematol 12 1999 329 341
7. J.F. Leeuwenberg, E.F. Smeets, J.J. Neefjes E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro Immunology 77 1992 543 549
8. N.A. Nelken, S.R. Coughlin, D. Gordon Monocyte chemoattractant protein-1 in human atheromatous plaques J Clin Invest 88 1991 1121 1127
9. K.K. Ray, D.A. Morrow, C.M. Gibson Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy Eur Heart J 26 2005 440 446
10. U. Laufs, V. La Fata, J. Plutzky Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
11. H. Omori, H. Nagashima, Y. Tsurumi Direct in vivo evidence of a vascular statin a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects Br J Clin Pharmacol 54 2002 395 399
12. O. Hernandez-Perera, D. Perez-Sala, J. Navarro-Antolin Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 1998 2711 2719
13. S. Fichtlscherer, G. Rosenberger, D.H. Walter Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease Circulation 102 2000 1000 1006
14. S. Dimmeler, A. Aicher, M. Vasa H MG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway J Clin Invest 108 2001 391 397
15. D.H. Walter, K. Rittig, F.H. Bahlmann Statin therapy accelerates re-endothelialization a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells Circulation 105 2002 3017 3024
16. M. Vasa, S. Fichtlscherer, K. Adler Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease Circulation 103 2001 2885 2890
17. B. Assmus, C. Urbich, A. Aicher HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes Circ Res 92 2003 1049 1055
18. S. Blankenberg, H.J. Rupprecht, C. Bickel Circulating cell adhesion molecules and death in patients with coronary artery disease Circulation 104 2001 1336 1342
19. W. Dichtl, J. Dulak, M. Frick H MG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells Arterioscler Thromb Vasc Biol 23 2003 58 63
20. I. Seljeflot, S. Tonstad, I. Hjermann Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease Atherosclerosis 162 2002 179 185
21. I. Inoue, S. Goto, K. Mizotani Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells Life Sci 67 2000 863 876
22. A.H. Wagner, M. Gebauer, B. Guldenzoph 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells Arterioscler Thromb Vasc Biol 22 2002 1784 1789
23. U. Schonbeck, N. Gerdes, N. Varo Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells Circulation 106 2002 2888 2893
24. V. Salomaa, C. Matei, N. Aleksic Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study a case-cohort study Lancet 353 1999 1729 1734
25. A. Sambola, J. Osende, J. Hathcock Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity Circulation 107 2003 973 977
26. K. Misumi, H. Ogawa, H. Yasue Comparison of plasma tissue factor levels in unstable and stable angina pectoris Am J Cardiol 81 1998 22 26
27. P. Bogaty, P. Poirier, S. Simard Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina Circulation 103 2001 3062 3068
28. T.W. Meade, V. Ruddock, Y. Stirling Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
29. K. Masamura, K. Oida, H. Kanehara Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family Arterioscler Thromb Vasc Biol 23 2003 512 517
30. M. Eto, T. Kozai, F. Cosentino Statin prevents tissue factor expression in human endothelial cells role of Rho/Rho-kinase and Akt pathways Circulation 105 2002 1756 1759
31. C. Bickel, H.J. Rupprecht, S. Blankenberg Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion Int J Cardiol 82 2002 25 31
32. T. Bourcier, P. Libby HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells Arterioscler Thromb Vasc Biol 20 2000 556 562
33. F. Bruni, L. Puccetti, A.L. Pasqui Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects Clin Exp Med 3 2003 45 53
34. E. Porreca, C. DiFebbo, C. Amore Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients Thromb Haemost 84 2000 789 793
35. A. Undas, K.E. Brummel, J. Musial Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation Circulation 103 2001 2248 2253
36. G. Liuzzo, S.L. Kopecky, R.L. Frye Perturbation of the T-cell repertoire in patients with unstable angina Circulation 100 1999 2135 2139
37. J. Auer, R. Berent, E. Labetanig Serum neopterin and activity of coronary artery disease Heart Dis 3 2001 297 301
38. W.H. Lee, Y. Lee, J.R. Kim Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients Exp Mol Med 31 1999 159 164
39. X. Garcia-Moll, D. Cole, E. Zouridakis Increased serum neopterin a marker of coronary artery disease activity in women Heart 83 2000 346 350
40. S. Baldus, C. Heeschen, T. Meinertz Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445
41. B. Lindahl, H. Toss, A. Siegbahn Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease (see comments) N Engl J Med 343 2000 1139 1147
42. L.M. Biasucci, G. Liuzzo, G. Fantuzzi Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Circulation 99 1999 2079 2084
43. Z. Mallat, P. Henry, R. Fressonnet Increased plasma concentrations of interleukin-18 in acute coronary syndromes Heart 88 2002 467 469
44. Y. Balbay, H. Tikiz, R.J. Baptiste Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction Angiology 52 2001 109 114
45. H. Yamashita, K. Shimada, E. Seki Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris Am J Cardiol 91 2003 133 136
46. C. Heeschen, S. Dimmeler, C.W. Hamm Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes Circulation 107 2003 2109 2114
47. N. Varo, J.A. deLemos, P. Libby Soluble CD40L risk prediction after acute coronary syndromes Circulation 108 2003 1049 1052
48. E. Lutgens, K.B. Cleutjens, S. Heeneman Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype Proc Natl Acad Sci U S A 97 2000 7464 7469
49. G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 2001 687 692
50. G.K. Sukhova, J.K. Williams, P. Libby Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol Arterioscler Thromb Vasc Biol 22 2002 1452 1458
51. Z. Luan, A.J. Chase, A.C. Newby Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages Arterioscler Thromb Vasc Biol 23 2003 769 775
52. L.M. Blanco-Colio, B. Munoz-Garcia, J.L. Martin-Ventura 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes Circulation 108 2003 1506 1513
53. R. Hakamada-Taguchi, Y. Uehara, K. Kuribayashi Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development Circ Res 93 2003 948 956
54. K. Shimada, K. Miyauchi, H. Daida Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome from bedside to bench Circulation 109 2004 e213 e214
55. G. Neurauter, B. Wirleitner, A. Laich Atorvastatin suppresses interferon-gamma-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines Clin Exp Immunol 131 2003 264 267
56. A. Rezaie-Majd, G.W. Prager, R.A. Bucek Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients Arterioscler Thromb Vasc Biol 23 2003 397 403
57. A. Rezaie-Majd, T. Maca, R.A. Bucek Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients Arterioscler Thromb Vasc Biol 22 2002 1194 1199
58. V. Pasceri, J.T. Willerson, E.T. Yeh Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
59. J. Cermak, N.S. Key, R.R. Bach C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 1993 513 520
60. D.Z. Hillyard, A.G. Jardine, K.J. McDonald Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes Atherosclerosis 172 2004 219 228
61. R.M. Bell, D.M. Yellon Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway J Am Coll Cardiol 41 2003 508 515
62. T. Vollmer, L. Key, V. Durkalski Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
63. S. Youssef, O. Stuve, J.C. Patarroyo The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78 84
64. D.W. McCarey, I.B. McInnes, R. Madhok Trial of Atorvastatin in Rheumatoid Arthritis (TARA) double-blind, randomised placebo-controlled trial Lancet 363 2004 2015 2021
65. B. Wolozin, W. Kellman, P. Ruosseau Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
66. K. Fassbender, M. Simons, C. Bergmann Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc Natl Acad Sci U S A 98 2001 5856 5861
67. S.M. Kent, P.J. Flaherty, L.C. Coyle Effect of atorvastatin and pravastatin on serum C-reactive protein Am Heart J 145 2003 e8
68. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
69. S. Kinlay, G.G. Schwartz, A.G. Olsson High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566
70. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
71. P.M. Ridker, C.P. Cannon, E. Braunwald Response to C-reactive protein levels and outcomes after statin therapy (letter) N Engl J Med 352 2005 1603 1604